CARPRIEVE TABS 100MG (TUB) PK 100 - NORBROOK LABS

NORBROOK LABS

CARPRIEVE TABS 100MG (TUB) PK 100
NORBROOK LABS

LEGAL CLASSIFICATION: POM-V 

THIS MEDICINE REQUIRES A PRESCRIPTION. 

This can be uploaded on this page or it can be sent to mail@vets4u.uk.   

We also require information about you and your Pet for us to be able to dispense your Pets medicine, please provide us with all your up to date information in the Question boxes. 

A link the the Medicine SPC on the VMD Product database can be found here: VMD Product Database

 A link the product Information can be found on the NOAH Compendium here: NOAH Data sheets


£0.00
£78.68
Earn0
reward points



Oh No! This product is out of stock. Would you like to know when it's avaliable again?

  • Dosage and Administration

    DOSAGE AND ADMINISTRATION

    Amounts to be administered and administration route
    For oral administration.
    4 mg carprofen per kg bodyweight per day.
    An initial dose of 4 mg carprofen per kg bodyweight per day given as a single dose or in two equally divided doses. The daily dose may be reduced, subject to clinical response.
    Duration of treatment will be dependent upon the response seen. Long-term treatment should be under regular veterinary supervision.
    Do not exceed the stated dose.
    To extend analgesic and anti-inflammatory cover post-operatively parenteral pre-operative treatment with an injectable Carprofen product may be followed with Carprofen Tablets at 4 mg/kg/day for up to 5 days.
    Return any halved tablets to the original pack and use at the next administration.
    Any halved tablets remaining after the last administration of the product must be discarded.
  • Contra-Indications , Warnings

    CONTRA-INDICATIONS, WARNINGS, ETC

    Contraindications
    Do not use in cats.
    Do not use in pregnant or lactating bitches.
    Do not use in puppies less than 4 months of age.
    Do not use in animals with known hypersensitivity to the active substance or to any of the excipients.”
    Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.
    Special warnings for each target species
    Refer to Sections, "Contraindications" and "Special precautions for use"
    Special precautions for use
    Special precautions for use in animals
    Use in aged dogs may involve additional risk.
    If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
    NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
    Avoid use in any dehydrated, hypoproteinemic, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
    Refer to section, "Interaction with other medicinal products and other forms of interaction"
    Special precautions to be taken by the person administering the veterinary medicinal product to animals
    In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet.
    Wash hands after handling the product.
    Adverse reactions (frequency and seriousness)
    Typical undesirable effects associated with NSAIDs such as vomiting, soft faeces/diarrhoea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
    If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.
    As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.
    Use during pregnancy, lactation or lay
    Studies in laboratory species (rat and rabbit) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose. The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.
    Interaction with other medicinal products and other forms of interaction
    Do not administer other NSAIDs and glucocorticoids concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs, which can lead to toxic effects.
    Concurrent administration of potential nephrotoxic drugs should be avoided.
    Amounts to be administered and administration route
    For oral administration.
    4 mg carprofen per kg bodyweight per day.
    An initial dose of 4 mg carprofen per kg bodyweight per day given as a single dose or in two equally divided doses. The daily dose may be reduced, subject to clinical response.
    Duration of treatment will be dependent upon the response seen. Long-term treatment should be under regular veterinary supervision.
    Do not exceed the stated dose.
    To extend analgesic and anti-inflammatory cover post-operatively parenteral pre-operative treatment with an injectable Carprofen product may be followed with Carprofen Tablets at 4 mg/kg/day for up to 5 days.
    Return any halved tablets to the original pack and use at the next administration.
    Any halved tablets remaining after the last administration of the product must be discarded.
    Overdose (symptoms, emergency procedures, antidotes), if necessary
    Do not exceed the stated dose. There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.
    Withdrawal Period(s)
    Not applicable.

    PHARMACEUTICAL PRECAUTIONS

    Special precautions for use
    Special precautions for use in animals
    Use in aged dogs may involve additional risk.
    If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
    NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
    Avoid use in any dehydrated, hypoproteinemic, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
    Refer to section, "Interaction with other medicinal products and other forms of interaction"
    Special precautions to be taken by the person administering the veterinary medicinal product to animals
    In the event of accidental ingestion of the tablets, seek medical advice and show the doctor the package leaflet.
    Wash hands after handling the product.

    PACKAGING QUANTITIES


    Carprieve 100mg Tablets are supplied in either:
    Polypropylene Snap Secure Tubs containing 14, 30 or 100 tablets, sealed with a white low density Polyethylene Snap Secure Cap, or
    Aluminium-Aluminium blister strips of 10 tablets in cartons containing 10, 20, 30, 50, 60, 70, 100, 140, 180, 200, 250, 280, 300, 500 or 1000 tablets.
  • Further Info

    FURTHER INFORMATION

    List of excipients
    Tartrazine (E102)
    Microcrystalline cellulose
    Lactose monohydrate
    Croscarmellose sodium
    Povidone K 30
    Sodium laurilsulphate
    Magnesium stearate
    Incompatibilities
    Not applicable.
    Shelf-life
    Shelf life of the veterinary medicinal product as packaged for sale: 2 years
    Special precautions for storage
    Do not store above 25°C.
    Store in a dry place.
    Protect from light.
    Special precautions for the disposal of unused veterinary medicinal products or waste materials
    Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

    MARKETING AUTHORISATION NUMBER

    Vm 02000/4283

    GTIN (GLOBAL TRADE ITEM NO)

    GTIN description:Carprieve 100mg Tablets (100 Pack)
    GTIN:5023534009160
    GTIN description:Carprieve 100mg Tablets
    GTIN:5023534009153

Ask us a question